Andere Kunden interessierten sich auch für
![Expression von TOP2A mRNA, BCL-2 mRNA und KI-67 mRNA bei Brustkrebs]( "Expression von TOP2A mRNA, BCL-2 mRNA und KI-67 mRNA bei Brustkrebs")
Expression von TOP2A mRNA, BCL-2 mRNA und KI-67 mRNA bei Brustkrebs54,90 €![Espressione di TOP2A mRNA, BCL-2 mRNA e KI-67 mRNA nel cancro al seno]( "Espressione di TOP2A mRNA, BCL-2 mRNA e KI-67 mRNA nel cancro al seno")
Espressione di TOP2A mRNA, BCL-2 mRNA e KI-67 mRNA nel cancro al seno36,99 €![Expressão de TOP2A mRNA, BCL-2 mRNA & KI-67 mRNA em cancro da mama]( "Expressão de TOP2A mRNA, BCL-2 mRNA & KI-67 mRNA em cancro da mama")
Expressão de TOP2A mRNA, BCL-2 mRNA & KI-67 mRNA em cancro da mama36,99 €![Expression de l'ARNm TOP2A, de l'ARNm BCL-2 et de l'ARNm KI-67 dans le cancer du sein]( "Expression de l'ARNm TOP2A, de l'ARNm BCL-2 et de l'ARNm KI-67 dans le cancer du sein")
Expression de l'ARNm TOP2A, de l'ARNm BCL-2 et de l'ARNm KI-67 dans le cancer du sein36,99 €![Jexpressiq TOP2A mRNK, BChL-2 mRNK i KI-67 mRNK w rake molochnoj zhelezy]( "Jexpressiq TOP2A mRNK, BChL-2 mRNK i KI-67 mRNK w rake molochnoj zhelezy")
Jexpressiq TOP2A mRNK, BChL-2 mRNK i KI-67 mRNK w rake molochnoj zhelezy16,99 €![Inhibition of human telomerase reverse transcriptase mRNA expression]( "Inhibition of human telomerase reverse transcriptase mRNA expression")
Inhibition of human telomerase reverse transcriptase mRNA expression23,99 €![Bcl-2 expression in prostatic adenocarcinoma]( "Bcl-2 expression in prostatic adenocarcinoma")
Bcl-2 expression in prostatic adenocarcinoma32,99 €
Breast cancer is the most commonly diagnosed cancer and the cause of death from cancer in women worldwide (Jemal et al., 2011), The incidence of breast cancer in the world ranges from 1.38 million new cases per year and deaths from breast cancer ranges from 458 400 (Jemal et al., 2011), Data from Jakarta cancer registry shows that breast cancer is the cancer with the highest incidence with 18.6 incidents per 100,000 population per year(Wahidin et al., 2012), The majority of breast cancer patients in Indonesia comes in an advanced stage, 63% in stage III and IV at diagnosis(Rhodes and Yip, 2011), Internal data Wahidin Sudirohusodo hospital Makassar in 2014, Chemotherapy performed on 247 patients with breast cancer, neoadjuvant chemotherapy 145 (59%) and adjuvant 102 (41%), the cumulative response rate to chemotherapy; 2% complete response, partial response 78%, 15% stable disease, progressive disease of 5%(Prihantono et al, 2015),